MTNB

Business Context and Reporting Period

Company: Matinas BioPharma Holdings, Inc. (MTNB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: A clinical-stage biopharmaceutical company focused on its lipid nanocrystal (LNC) platform, specifically advancing the lead product candidate MAT2203. The company is currently pausing significant development activities to conserve cash and seek strategic partnerships.

Key Financial Metrics

Note: The company reported no revenue for the periods presented. The significant reduction in operating expenses is primarily due to a pause in clinical trial activities and workforce reductions.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses for the six months ended June 30, 2025, decreased to $3.8 million from $11.7 million in the same period in 2024.
  • R&D Expenses: Dropped from $6.8 million (YTD 2024) to $85 thousand (YTD 2025) due to the pause in the MAT2203 development program and headcount reductions.
  • G&A Expenses: Decreased from $4.9 million (YTD 2024) to $3.7 million (YTD 2025), driven by lower stock-based compensation and reduced headcount.
• Warrant Liability Reclassification: A non-cash loss of $3.2 million was recognized in YTD 2025 related to the change in fair value of warrant liabilities prior to their reclassification to equity on June 26, 2025, following an amendment to the warrant terms.
• Asset Sales: The company sold unused laboratory equipment for a net gain of $110 thousand during the quarter.
• Financing Activity: The company raised $3.3 million in gross proceeds through a private placement of Series C Convertible Preferred Stock and warrants in two tranches (February and April 2025).

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. Cash on hand ($6.5 million) is not sufficient to fund operations beyond the next twelve months.
• Strategic Pivot: The primary strategy is to secure a partner to monetize MAT2203 or raise non-dilutive capital. The company is actively conserving cash and evaluating strategic options, including potential mergers or asset in-licensing.
• Financing Restrictions: Under the terms of the recent Series C Preferred Stock purchase agreement, the company is prohibited from issuing common stock or equivalents until November 2025, limiting immediate equity fundraising options.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting regarding the processing of non-routine transactions (specifically indefinite-lived asset impairment assessments). Remediation is ongoing but not yet complete.
• Future Expenses: Expenses are expected to remain low in the near term but will increase significantly if the company secures funding to initiate Phase 3 trials or achieves commercial launch.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.5 million cash balance against the burn rate and the timeline for securing a strategic partner or additional financing.
• Financing Blockade: Confirm the impact of the November 2025 restriction on issuing common stock equivalents on the company's ability to raise capital before cash is depleted.
• Warrant Accounting: Review the details of the warrant amendment and reclassification to equity to ensure no future fair value volatility will impact the income statement.
• Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness in internal controls over financial reporting.
• Partnership Progress: Assess any updates regarding the search for a partner to monetize MAT2203, which is critical to the company's survival strategy.